Translation Accelerator Core
Translation Accelerator Core
批准号:
10514268
负责人:
Kevin V Grimes
金额:
$1478.38万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-05-16 至 2025-04-30
关键词:
2019-nCoVAntiviral AgentsAreaBiological SciencesCOVID-19 therapeuticsChemistryClinical TrialsCollectionComputer ModelsConsultDevelopmentDrug KineticsEnsureEnvironmentExonsFormulationFundingGoalsHamstersHeadHumanIn VitroIndustryInfrastructureKnowledgeLeadLeadershipMedicineMissionModelingMusOutpatientsPharmaceutical ChemistryPharmaceutical PreparationsPharmacologyProcessProdrugsPropertyRNA VirusesRegulatory AffairsResearchResearch PersonnelResourcesRodentScienceSeriesServicesStructure-Activity RelationshipSystemToxicologyTranslationsValidationanalytical methodcommercializationcomputational chemistrydesigndrug metabolismefficacy studyin vivoindustry partnerinnovationlead optimizationmethod developmentnonhuman primatepandemic diseasepandemic preparednesspre-clinicalpreclinical developmentscale upscreeningsmall moleculevirtualvirtual library
中文摘要
摘要:翻译加速器核心的目标是提供适当的专业知识和
英文摘要
ABSTRACT: The goal of the Translation Accelerator Core is to provide the appropriate expertise and
resources to advance the translational efforts of the Stanford AViDD Center projects with industry-level rigor.
Embedded in the Core is an Industry Consultants Consortium that will provide expert support for all key facets
of successful preclinical development—from lead identification, to lead optimization, to nomination of a
development candidate, and appropriate IND-enabling studies. This preclinical development includes virtual
small molecule screening, computational chemistry and modeling, medicinal chemistry, in vitro characterization
of drug metabolism and pharmacokinetic (DMPK) properties, formulation, scale-up and process chemistry
including analytical methods development, in vivo toxicology and characterization of drug metabolism and
pharmacokinetic (DMPK) properties, and regulatory affairs. Finally, to ensure these efforts are efficient and
maximally productive, we have assembled a trio of world-class directors of research from industry, and
incorporated organizations and industry partners whose mission and resources are dedicated to helping
compelling lead molecules advance towards commercialization. Successful accomplishment of this Core’s
efforts will enable the development of new classes of outpatient antiviral therapeutics for SARS-CoV-2 and
other RNA viruses of pandemic potential.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金